Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q2 2026 (June 30)8holders +2
2new positions
0sold out
$0.01avg. 13F price*
At the end of Q2 2026, 8 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, up 2 from Q1 2026. 2 opened new positions and 0 sold out. The largest holders were LMR Partners LLP ($7K), Morgan Stanley ($2K) and Clear Street Group Inc. ($1K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $4 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 25,982 shares bought, net +25,982 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| LMR Partners LLP | — | No change | 539,588 | $7K |
| Morgan Stanley | — | No change | 146,439 | $2K |
| Clear Street Group Inc. | — | Add +0.4% | 79,033 | $1K |
| GTS Securities LLC | — | Add +0.7% | 41,301 | $537 |
| UBS Group AG | — | Add +56.9% | 6,567 | $85 |
| Wolverine Asset Management LLC | — | Add +81.6% | 3,289 | $42 |
| Toronto Dominion Bank | — | New | 300 | $4 |
| Virtu Financial LLC | — | New | 21,223 | $0 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.